UAB Digital Repository of Documents 10 records found  Search took 0.01 seconds. 
1.
18 p, 8.9 MB Reducing MYC's transcriptional footprint unveils a good prognostic gene signature in melanoma / Zacarías-Fluck, Mariano F (Vall d'Hebron Institut d'Oncologia) ; Massó Vallés, Daniel (Vall d'Hebron Institut d'Oncologia) ; Giuntini, Fabio (Vall d'Hebron Institut d'Oncologia) ; González-Larreategui, Íñigo (Vall d'Hebron Institut d'Oncologia) ; Kaur, Jastrinjan (Vall d'Hebron Institut d'Oncologia) ; Casacuberta-Serra, Sílvia (Vall d'Hebron Institut d'Oncologia) ; Jauset, Toni (Vall d'Hebron Institut d'Oncologia) ; Martínez-Martín, Sandra (Vall d'Hebron Institut d'Oncologia) ; Martín-Fernández, Génesis (Vall d'Hebron Institut d'Oncologia) ; Serrano del Pozo, Erika (Vall d'Hebron Institut d'Oncologia) ; Foradada Felip, Laia (Vall d'Hebron Institut d'Oncologia) ; Grueso, Judit (Vall d'Hebron Institut d'Oncologia) ; Nonell, Lara (Vall d'Hebron Institut d'Oncologia) ; Beaulieu, Marie-Eve (Vall d'Hebron Institut d'Oncologia) ; Whitfield, Jonathan R. (Vall d'Hebron Institut d'Oncologia) ; Soucek, Laura (Vall d'Hebron Institut d'Oncologia) ; Universitat Autònoma de Barcelona
MYC's key role in oncogenesis and tumor progression has long been established for most human cancers. In melanoma, its deregulated activity by amplification of 8q24 chromosome or by upstream signaling coming from activating mutations in the RAS/RAF/MAPK pathway-the most predominantly mutated pathway in this disease-turns MYC into not only a driver but also a facilitator of melanoma progression, with documented effects leading to an aggressive clinical course and resistance to targeted therapy. [...]
2023 - 10.1101/gad.350078.122
Genes & Development, Vol. 37 (april 2023) , p. 303-320  
2.
10 p, 912.2 KB Pharmacokinetic analysis of omomyc shows lasting structural integrity and long terminal half-Life in tumor tissue / Beaulieu, Marie-Eve (Peptomyc SL) ; Martínez-Martín, Sandra (Peptomyc SL) ; Kaur, Jastrinjan (Vall d'Hebron Institut d'Oncologia) ; Castillo Cano, Virginia (Peptomyc SL) ; Massó Vallés, Daniel (Peptomyc SL) ; Foradada Felip, Laia (Peptomyc SL) ; López-Estévez, Sergio (Peptomyc SL) ; Serrano del Pozo, Erika (Vall d'Hebron Institut d'Oncologia) ; Thabussot, Hugo (Peptomyc SL) ; Soucek, Laura (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
MYC is an oncoprotein causally involved in the majority of human cancers and a most wanted target for cancer treatment. Omomyc is the best-characterized MYC dominant negative to date. In the last years, it has been developed into a therapeutic miniprotein for solid tumor treatment and recently reached clinical stage. [...]
2023 - 10.3390/cancers15030826
Cancers, Vol. 15, Issue 3 (February 2023) , art. 826  
3.
21 p, 11.5 MB MYC Inhibition Halts Metastatic Breast Cancer Progression by Blocking Growth, Invasion, and Seeding / Massó Vallés, Daniel (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Beaulieu, Marie-Eve (Hospital Universitari Vall d'Hebron) ; Jauset González, Toni (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Giuntini, Fabio (Vall d'Hebron Institut d'Oncologia) ; Zacarías-Fluck, Mariano F (Vall d'Hebron Institut d'Oncologia) ; Foradada Felip, Laia (Hospital Universitari Vall d'Hebron) ; Martínez-Martín, Sandra (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Serrano, Erika (Vall d'Hebron Institut d'Oncologia) ; Martín-Fernández, Génesis (Vall d'Hebron Institut d'Oncologia) ; Casacuberta-Serra, Sílvia (Hospital Universitari Vall d'Hebron) ; Castillo Cano, Virginia (Hospital Universitari Vall d'Hebron) ; Kaur, Jastrinjan (Vall d'Hebron Institut d'Oncologia) ; López-Estévez, Sergio (Hospital Universitari Vall d'Hebron) ; Morcillo, Miguel Ángel (Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (Espanya)) ; Alzrigat, Mohammad (Karolinska Institutet (Suècia). Department of Microbiology, Tumor and Cell Biology) ; Mahmoud, Loay (Karolinska Institutet (Suècia). Department of Microbiology, Tumor and Cell Biology) ; Luque-García, Antonio (Vall d'Hebron Institut d'Oncologia) ; Escorihuela, Marta (Vall d'Hebron Institut d'Oncologia) ; Guzman, Marta (Vall d'Hebron Institut d'Oncologia) ; Arribas, Joaquín V (Institució Catalana de Recerca i Estudis Avançats) ; Serra, Violeta (Vall d'Hebron Institut d'Oncologia) ; Larsson, Lars-Gunnar (Karolinska Institutet (Suècia). Department of Microbiology, Tumor and Cell Biology) ; Whitfield, Jonathan R. (Vall d'Hebron Institut d'Oncologia) ; Soucek, Laura (Institució Catalana de Recerca i Estudis Avançats)
While MYC role in metastasis has been long controversial, this manuscript demonstrates that MYC inhibition by either transgenic expression or pharmacologic use of the recombinantly produced Omomyc miniprotein exerts antitumor and antimetastatic activity in breast cancer models in vitro and in vivo, suggesting its clinical applicability.
2022 - 10.1158/2767-9764.CRC-21-0103
Cancer Research Communications, Vol. 2 (february 2022) , p. 110-130  
4.
27 p, 2.3 MB Structural and biophysical insights into the function of the intrinsically disordered Myc oncoprotein / Beaulieu, Marie-Eve (Peptomyc S.L.) ; Castillo, Francisco (Peptomyc S.L.) ; Soucek, Laura (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
Myc is a transcription factor driving growth and proliferation of cells and involved in the majority of human tumors. Despite a huge body of literature on this critical oncogene, our understanding of the exact molecular determinants and mechanisms that underlie its function is still surprisingly limited. [...]
2020 - 10.3390/cells9041038
Cells, Vol. 9, Issue 4 (April 2020) , art. 1038  
5.
10 p, 3.3 MB The Wnt signaling receptor Fzd9 is essential for Myc-driven tumorigenesis in pancreatic islets / Zacarías-Fluck, Mariano F. (Vall d'Hebron Institut d'Oncologia) ; Jauset González, Toni (Hospital Universitari Vall d'Hebron) ; Martínez-Martín, Sandra (Vall d'Hebron Institut d'Oncologia) ; Kaur, Jastrinjan (Vall d'Hebron Institut d'Oncologia) ; Casacuberta-Serra, Sílvia (Hospital Universitari Vall d'Hebron) ; Massó Vallés, Daniel (Vall d'Hebron Institut d'Oncologia) ; Serrano del Pozo, Erika (Vall d'Hebron Institut d'Oncologia) ; Martín-Fernández, Génesis (Vall d'Hebron Institut d'Oncologia) ; González-Larreategui, Íñigo (Vall d'Hebron Institut d'Oncologia) ; López-Estévez, Sergio (Hospital Universitari Vall d'Hebron) ; Brown-Swigart, Lamorna (Department of Pathology and Helen Diller Family Comprehensive Cancer Center, University of California) ; Beaulieu, Marie-Eve (Vall d'Hebron Institut d'Oncologia) ; Whitfield, Jonathan R. (Vall d'Hebron Institut d'Oncologia) ; Madan, Babita (Program in Cancer and Stem Cell Biology, Duke-National University of Singapore (NUS) Medical School) ; Virshup, David M. (Program in Cancer and Stem Cell Biology, Duke-National University of Singapore (NUS) Medical School) ; Evan, Gerard I (Department of Biochemistry, University of Cambridge) ; Soucek, Laura (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
Zacarías-Fluck, et al identify and validate the Wnt receptor Fzd9 as a key effector of Myc-Wnt signaling cross-talk in a mouse model of Myc-driven pancreatic insulinomas. The huge cadre of genes regulated by Myc has obstructed the identification of critical effectors that are essential for Myc-driven tumorigenesis. [...]
2021 - 10.26508/lsa.201900490
Life Science Alliance, Vol. 4 (march 2021)  
6.
986.5 KB Finding MYCure / Beaulieu, Marie-Eve (Peptomyc S.L.) ; Soucek, Laura (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
Inhibiting the nuclear protein MYC involved in the majority of human cancers has long been considered an impossible mission and several technical challenges have discouraged the development of MYC inhibitory strategies. [...]
2019 - 10.1080/23723556.2019.1618178
Molecular & cellular oncology, Vol. 6, Num. 5 (June 2019) , art. e1618178  
7.
9 p, 3.4 MB Targeting antitumoral proteins to breast cancer by local administration of functional inclusion bodies / Pesarrodona Roches, Mireia (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ; Jauset González, Toni (Vall d'Hebron Institut d'Oncologia) ; Díaz Riascos, Zamira Vanessa (Centro de Investigación Biomédica en Red) ; Sánchez Chardi, Alejandro (Universitat de Barcelona. Departament de Biologia Evolutiva, Ecologia i Ciències Ambientals) ; Beaulieu, Marie-Eve (Vall d'Hebron Institut d'Oncologia) ; Seras-Franzoso, Joaquin (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Sánchez García, Laura 1992- (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ; Baltà Foix, Ricardo. (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Mancilla, Sandra (Centro de Investigación Biomédica en Red) ; Fernández Caparrós, Yolanda (Centro de Investigación Biomédica en Red) ; Rinas, Ursula (Leibniz University of Hannover. Helmholtz Centre for Infection Research) ; Schwartz, Simó (Centro de Investigación Biomédica en Red) ; Soucek, Laura (Vall d'Hebron Institut d'Oncologia) ; Villaverde Corrales, Antonio (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia) ; Abasolo, Ibane (Centro de Investigación Biomédica en Red) ; Vázquez Gómez, Esther (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí")
Two structurally and functionally unrelated proteins, namely Omomyc and p31, are engineered as CD44-targeted inclusion bodies produced in recombinant bacteria. In this unusual particulate form, both types of protein materials selectively penetrate and kill CD44 tumor cells in culture, and upon local administration, promote destruction of tumoral tissue in orthotropic mouse models of human breast cancer. [...]
2019 - 10.1002/advs.201900849
Advanced science, Vol. 6, issue 18 (Sep. 2019) , art. 1900849  
8.
13 p, 5.3 MB BET inhibition is an effective approach against KRAS-driven PDAC and NSCLC / Jauset González, Toni (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Massó Vallés, Daniel (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Martínez Martín, Sandra (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Beaulieu, Marie-Eve (Vall d'Hebron Institut d'Oncologia) ; Foradada Felip, Laia (Vall d'Hebron Institut d'Oncologia) ; Fiorentino, Francesco Paolo (Department of Biomedical Sciences, University of Sassari) ; Yokota, Jun (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Haendler, Bernard (Drug Discovery, Bayer AG) ; Siegel, Stephan (Drug Discovery, Bayer AG) ; Whitfield, Jonathan R. (Vall d'Hebron Institut d'Oncologia) ; Soucek, Laura (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
Effectively treating KRAS-driven tumors remains an unsolved challenge. The inhibition of downstream signaling effectors is a way of overcoming the issue of direct targeting of mutant KRAS, which has shown limited efficacy so far. [...]
2018 - 10.18632/oncotarget.24648
Oncotarget, Vol. 9 (april 2018) , p. 18734-18746  
9.
13 p, 1.2 MB Strategies to Inhibit Myc and Their Clinical Applicability / Whitfield, Jonathan R. (Vall d'Hebron Institut d'Oncologia) ; Beaulieu, Marie-Eve (Hospital Universitari Vall d'Hebron) ; Soucek, Laura (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
Myc is an oncogene deregulated in most-perhaps all-human cancers. Each Myc family member, c-, L-, and N-Myc, has been connected to tumor progression and maintenance. Myc is recognized as a "most wanted" target for cancer therapy, but has for many years been considered undruggable, mainly due to its nuclear localization, lack of a defined ligand binding site, and physiological function essential to the maintenance of normal tissues. [...]
2017 - 10.3389/fcell.2017.00010
Frontiers in Cell and Developmental Biology, Vol. 5 (February 2017) , art. 10  
10.
11 p, 1.8 MB Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis / Annibali, Daniela (University of California) ; Whitfield, Jonathan R. (Vall d'Hebron Institut d'Oncologia) ; Favuzzi, Emilia (Università La Sapienza) ; Jauset González, Toni (Universitat Autònoma de Barcelona) ; Serrano, Erika (Universitat Autònoma de Barcelona) ; Cuartas, Isabel (Universitat Autònoma de Barcelona) ; Redondo Campos, Sara (Universitat Autònoma de Barcelona) ; Folch, Gerard (Universitat Autònoma de Barcelona) ; Gonzàlez-Juncà, Alba (Universitat Autònoma de Barcelona) ; Sodir, Nicole M. (University of Cambridge) ; Massó Vallés, Daniel (Universitat Autònoma de Barcelona) ; Beaulieu, Marie-Eve (Universitat Autònoma de Barcelona) ; Swigart, Lamorna B. (University of California) ; Mc Gee, Margaret M. (University College Dublin) ; Somma, Maria Patrizia (Università La Sapienza) ; Nasi, Sergio (Università La Sapienza) ; Seoane Suárez, Joan (Institució Catalana de Recerca i Estudis Avançats) ; Evan, Gerard I. (University of Cambridge) ; Soucek, Laura (Universitat Autònoma de Barcelona)
Gliomas are the most common primary tumours affecting the adult central nervous system and respond poorly to standard therapy. Myc is causally implicated in most human tumours and the majority of glioblastomas have elevated Myc levels. [...]
2014 - 10.1038/ncomms5632
Nature communications, Vol. 5 (August 2014) , art. 4632  

See also: similar author names
11 Beaulieu, Marie-Eve
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.